Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 11/20 | 0.61 |
| ▸ | LPAR2 | Q9HBW0 | 7/20 | 0.61 |
| ▸ | LPAR1 | Q92633 | 6/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | ESR1 | P03372 | 1/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.48 |
| ▸ | CDC25A | P30304 | 1/20 | 0.48 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.48 |
| ▸ | AKT1 | P31749 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11297315 | 1.00 | LPAR3 (0.61) | LPAR3LPAR2LPAR1CYP3A4TP53 | |
| SCHEMBL11289118 | 1.00 | LPAR3 (0.61) | LPAR3LPAR2LPAR1CYP3A4TP53 | |
| SCHEMBL29151408 | 1.00 | LPAR3 (0.61) | LPAR3LPAR2LPAR1CYP3A4TP53 | |
| SCHEMBL3129987 | 1.00 | LPAR3 (0.61) | LPAR3LPAR2LPAR1CYP3A4TP53 | |
| SCHEMBL11292235 | 1.00 | LPAR3 (0.61) | LPAR3LPAR2LPAR1CYP3A4TP53 | |
| SCHEMBL11290063 | 1.00 | LPAR3 (0.61) | LPAR3LPAR2LPAR1CYP3A4TP53 | |
| SCHEMBL25170776 | 1.00 | LPAR3 (0.61) | LPAR3LPAR2LPAR1CYP3A4TP53 | |
| SCHEMBL6263500 | 1.00 | LPAR3 (0.61) | LPAR3LPAR2LPAR1CYP3A4TP53 | |
| SCHEMBL1261030 | 1.00 | LPAR3 (0.61) | LPAR3LPAR2LPAR1CYP3A4TP53 | |
| SCHEMBL6561892 | 1.00 | LPAR3 (0.61) | LPAR3LPAR2LPAR1CYP3A4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020173489-A1 | COMPOSITIONS CONTAINING A MIXTURE OF PHOSPHOROUS COMPOUNDS AND ALKYLGLYCEROLS | MAX-PLANCK-GESSELSCHAFT ZUR FORDERUNG DER WISSENSCHAFTER E.V. (DE) | 2002-11-21 | — | — | US | disclosed |
| US-5916884-A | CYTOTOXIC THERAPEUTIC COMPOUND; ANTITUMOR AGENT | MAX-PLANCK-GESELLSCHAFT ZUR FOEDERUNG DER WISSENSCHAFTEN (DE) | 1999-06-29 | — | — | US | disclosed |
| EP-0248062-B1 | MEDICAMENTS | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 1992-05-06 | — | — | EP | disclosed |
| EP-0225608-A2 | Medicine | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 1987-06-16 | — | — | EP | disclosed |
| EP-0002062-B1 | CYCLIC ORGANOPHOSPHORUS COMPOUNDS, METHOD FOR THEIR PREPARATION AND THEIR USE | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 1982-05-05 | — | — | EP | disclosed |
| EP-0002062-A1 | Cyclic organophosphorus compounds, method for their preparation and their use | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 1979-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020173489-A1 | COMPOSITIONS CONTAINING A MIXTURE OF PHOSPHOROUS COMPOUNDS AND ALKYLGLYCEROLS | PHOSPHO1, PLCG2, PPIP5K2 | LPAR3 41/4885LPAR2 65/4885LPAR1 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.